Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)

v3.24.3
Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Aug. 31, 2024
USD ($)
shares
Dec. 31, 2021
USD ($)
Sep. 30, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Number of Operating Segments | segment       2        
Payments to acquire investment in Spear Bio       $ 15,000        
Gain (loss) on equity method investment       374   $ (2,290)    
Number of expired vested stock options (in shares) | shares   804,162            
Total net pre-tax value of options that expired   $ 33,000            
Litigation charges       300   $ 0    
Accrued litigation       0        
Fiscal Year 2024 Restructuring Actions                
Positions eliminated during the period as a percentage         4.00%      
Protein Sciences                
Pre-tax restructuring charges             $ 200 $ 1,700
Protein Sciences | Fiscal Year 2024 Restructuring Actions                
Goodwill attributable to disposal group held for sale         $ 1,400      
Impairment charges related to the disposal group       0        
Protein Sciences | Current Assets, Held For Sale | Fiscal Year 2024 Restructuring Actions                
Property, plant and equipment attributable to disposal group held for sale       $ 9,500        
Wilson Wolf Corporation                
Investment in Wilson Wolf $ 232,000   $ 25,000          
Investment percentage 19.90%              
Forward Contract, Milestone, Multiple for Total Expected Payments       4.4        
Gain (loss) on equity method investment       $ 300        
Investment amount       241,000        
Wilson Wolf Corporation | First Part of Forward Contract                
Forward Contract, Milestone, Annual Revenue Required       92,000        
Forward Contract, Milestone, Annual EBITDA       55,000        
Wilson Wolf Corporation | Second Part of Forward Contract                
Forward Contract, Milestone, Annual Revenue Required       226,000        
Forward Contract, Milestone, Annual EBITDA       136,000        
Forward Contract, Additional Investment       1,000,000        
Spear Bio                
Payments to acquire investment in Spear Bio       15,000        
Spear Bio | Other assets                
Long-term investments       $ 15,000        
Selling, General and Administrative Expenses | Protein Sciences | Fiscal Year 2024 Restructuring Actions                
Asset Impairment Charges             $ 22,000